HK1203052A1 - Nanoparticles with enhanced mucosal penetration or decreased inflammation - Google Patents

Nanoparticles with enhanced mucosal penetration or decreased inflammation

Info

Publication number
HK1203052A1
HK1203052A1 HK15103577.8A HK15103577A HK1203052A1 HK 1203052 A1 HK1203052 A1 HK 1203052A1 HK 15103577 A HK15103577 A HK 15103577A HK 1203052 A1 HK1203052 A1 HK 1203052A1
Authority
HK
Hong Kong
Prior art keywords
nanoparticles
mucosal penetration
decreased inflammation
enhanced mucosal
enhanced
Prior art date
Application number
HK15103577.8A
Other languages
English (en)
Chinese (zh)
Inventor
Justin Hanes
Qingguo Xu
Nicholas Boylan
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/024344 external-priority patent/WO2012109363A2/en
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of HK1203052A1 publication Critical patent/HK1203052A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15103577.8A 2011-12-14 2015-04-13 Nanoparticles with enhanced mucosal penetration or decreased inflammation HK1203052A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161570413P 2011-12-14 2011-12-14
US201161570405P 2011-12-14 2011-12-14
PCT/US2012/024344 WO2012109363A2 (en) 2011-02-08 2012-02-08 Mucus penetrating gene carriers
PCT/US2012/069882 WO2013090804A2 (en) 2011-12-14 2012-12-14 Nanoparticles with enhanced mucosal penetration or decreased inflammation

Publications (1)

Publication Number Publication Date
HK1203052A1 true HK1203052A1 (en) 2015-10-16

Family

ID=48613373

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103577.8A HK1203052A1 (en) 2011-12-14 2015-04-13 Nanoparticles with enhanced mucosal penetration or decreased inflammation

Country Status (11)

Country Link
US (2) US20140329913A1 (ja)
EP (1) EP2790733B1 (ja)
JP (3) JP6308679B2 (ja)
KR (1) KR20140135948A (ja)
CN (1) CN104105507B (ja)
AU (2) AU2012351994B2 (ja)
BR (1) BR112014014262A2 (ja)
CA (1) CA2859046C (ja)
HK (1) HK1203052A1 (ja)
RU (1) RU2631599C2 (ja)
WO (1) WO2013090804A2 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
JP6308679B2 (ja) * 2011-12-14 2018-04-11 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
CA2871745C (en) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CA2916465C (en) * 2013-06-24 2023-05-23 Neximmune Humanized anti-cd28 antibodies and artificial antigen presenting cells
EP3027111A4 (en) * 2013-07-30 2017-08-23 Tarveda Therapeutics, Inc. Nanoparticle diagnostic and methods for treating disease
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
WO2016004290A1 (en) * 2014-07-03 2016-01-07 Bind Therapeutics, Inc. Targeted therapeutic nanoparticles and methods of making and using same
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
EP4445952A2 (en) 2014-12-15 2024-10-16 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
CN107427573B (zh) 2014-12-24 2022-12-27 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN105412935B (zh) * 2015-02-04 2019-02-19 四川大学 一种基于n-(2-羟丙基)甲基丙烯酰胺聚合物的纳米粒及其制备方法
CN104784116B (zh) * 2015-04-15 2017-05-24 武汉诺贝药业有限公司 一种n‑乙酰半胱氨酸口服制剂
EP3307324B1 (en) * 2015-06-15 2022-02-09 Innovitas Vitae S.r.l. Food supplement for use in a process of metabolic rebalancing
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3352749A4 (en) 2015-09-22 2019-09-04 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
JP2018533579A (ja) * 2015-10-30 2018-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 高分子量かつ密な被覆を有する粘液浸透粒子
AU2016353355B9 (en) 2015-11-12 2022-09-29 Graybug Vision, Inc. Aggregating microparticles for therapy
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
EP3295937A1 (en) * 2016-09-20 2018-03-21 Centre National De La Recherche Scientifique Nanoparticulate prodrugs
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018169960A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
US10420731B1 (en) * 2019-01-18 2019-09-24 King Saud University Method of synthesizing lignin-based nanocompositions
US20220339294A1 (en) * 2019-09-09 2022-10-27 Yale University Nanoparticles for selective tissue or cellular uptake
US20230074885A1 (en) * 2020-02-05 2023-03-09 The Johns Hopkins University Bortezomib-loaded nanoparticles
US20230414828A1 (en) * 2021-01-12 2023-12-28 Loria Pharmaceutical, Llc Multiple viscosity oil-in-water composition useful as an injectable filler and a scaffold for collagen growth
CN112915916B (zh) * 2021-01-29 2022-05-24 江南大学 一种pH刺激响应型胆汁盐Pickering复合乳化剂
CN114949245B (zh) * 2021-02-25 2024-08-16 香港中文大学 用于增强向皮肤角质形成细胞的局部递送和治疗皮肤炎症的自我治疗纳米颗粒
CN114983976B (zh) * 2022-06-23 2023-07-25 浙江工业大学 一种紫杉醇纳米制剂及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
EP1631270A4 (en) * 2003-05-20 2007-11-14 Erimos Pharmaceutical Llp METHOD AND COMPOSITIONS FOR DISTRIBUTING CATECHOLIC BUTANES FOR THE TREATMENT OF DISEASES
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
JP5131971B2 (ja) * 2005-12-26 2013-01-30 株式会社Ｌｔｔバイオファーマ 水溶性非ペプチド性低分子薬物含有ナノ粒子
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
JP5248487B2 (ja) * 2007-05-14 2013-07-31 株式会社Ｌｔｔバイオファーマ 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
ES2462090T5 (es) * 2008-06-16 2017-07-12 Pfizer Inc. Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
JP6308679B2 (ja) * 2011-12-14 2018-04-11 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子
WO2013110028A1 (en) * 2012-01-19 2013-07-25 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
JP2018533579A (ja) * 2015-10-30 2018-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 高分子量かつ密な被覆を有する粘液浸透粒子

Also Published As

Publication number Publication date
JP6590750B2 (ja) 2019-10-16
US20140329913A1 (en) 2014-11-06
EP2790733B1 (en) 2019-10-30
CN104105507A (zh) 2014-10-15
AU2012351994A1 (en) 2014-07-24
WO2013090804A3 (en) 2013-08-22
JP2015505855A (ja) 2015-02-26
BR112014014262A2 (pt) 2017-06-13
CA2859046C (en) 2019-10-22
AU2016200683A1 (en) 2016-02-18
US20210196829A1 (en) 2021-07-01
AU2016200683B2 (en) 2017-08-10
JP2018065882A (ja) 2018-04-26
CA2859046A1 (en) 2013-06-20
JP6308679B2 (ja) 2018-04-11
JP2016128522A (ja) 2016-07-14
WO2013090804A2 (en) 2013-06-20
CN104105507B (zh) 2020-03-24
AU2012351994B2 (en) 2015-11-05
EP2790733A2 (en) 2014-10-22
RU2631599C2 (ru) 2017-09-25
RU2014128578A (ru) 2016-02-10
KR20140135948A (ko) 2014-11-27

Similar Documents

Publication Publication Date Title
HK1203052A1 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
HUS2100012I1 (hu) 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
HK1215380A1 (zh) 增強粘膜滲透的納米粒子調配物
HK1203474A1 (en) Surface modified nanoparticles
EP2750662A4 (en) NANOPARTICLES TARGETING APOPTOSIS
HK1192839A1 (en) Amatoxin-conjugates with improved linkages
EP2747596A4 (en) CONCAVE-CONVEX ROLLER ASSEMBLY
GB201005601D0 (en) Ecapsulated nanoparticles
PL2691443T3 (pl) Sprzężone lipomery i ich zastosowania
EP2833926A4 (en) NEUROPHILIC NANOPARTICLES
ZA201205425B (en) Treatment with vb-201
ZA201402257B (en) Tapered structure construction
GB201216930D0 (en) Nanoparticles
PT2790739T (pt) Nanopartículas e utilizações das mesmas
EP2867155A4 (en) NANOSTRUCTURE COMPRISING FUNCTIONALLY DIFFERENT SIDES
PT2829180T (pt) Agente para aumento do teor em açúcar de frutos
SI2492413T1 (sl) Vrečast baldahin
ZA201409359B (en) Egg-carton with window
GB201221113D0 (en) Wind deflector
GB201209517D0 (en) Nanoparticles
ZA201406778B (en) Crossbow
PL2474682T3 (pl) Markiza
PL394027A1 (pl) Profil ogrodzenia
IL211389A0 (en) Wind gybe
GB201216325D0 (en) Fencing